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Abstract
IMPORTANCE—Associations between subclinical thyroid dysfunction and fractures are unclear 
and clinical trials are lacking.
OBJECTIVE—To assess the association of subclinical thyroid dysfunction with hip, nonspine, 
spine, or any fractures.
DATA SOURCES AND STUDY SELECTION—The databases of MEDLINE and EMBASE 
(inception to March 26, 2015) were searched without language restrictions for prospective cohort 
studies with thyroid function data and subsequent fractures.
DATA EXTRACTION—Individual participant data were obtained from 13 prospective cohorts in 
the United States, Europe, Australia, and Japan. Levels of thyroid function were defined as 
euthyroidism (thyroid-stimulating hormone [TSH], 0.45–4.49 mIU/L), subclinical 
hyperthyroidism (TSH <0.45 mIU/L), and subclinical hypothyroidism (TSH ≥4.50–19.99 mIU/L) 
with normal thyroxine concentrations.
MAIN OUTCOME AND MEASURES—The primary outcome was hip fracture. Any fractures, 
nonspine fractures, and clinical spine fractures were secondary outcomes.
RESULTS—Among 70 298 participants, 4092 (5.8%) had subclinical hypothyroidism and 2219 
(3.2%) had subclinical hyperthyroidism. During 762 401 person-years of follow-up, hip fracture 
occurred in 2975 participants (4.6%; 12 studies), any fracture in 2528 participants (9.0%; 8 
studies), nonspine fracture in 2018 participants (8.4%; 8 studies), and spine fracture in 296 
participants (1.3%; 6 studies). In age- and sex-adjusted analyses, the hazard ratio (HR) for 
subclinical hyperthyroidism vs euthyroidism was 1.36 for hip fracture (95% CI, 1.13–1.64; 146 
events in 2082 participants vs 2534 in 56 471); for any fracture, HR was 1.28 (95% CI, 1.06–1.53; 
121 events in 888 participants vs 2203 in 25 901); for nonspine fracture, HR was 1.16 (95% CI, 
0.95–1.41; 107 events in 946 participants vs 1745 in 21 722); and for spine fracture, HR was 1.51 
(95% CI, 0.93–2.45; 17 events in 732 participants vs 255 in 20 328). Lower TSH was associated 
with higher fracture rates: for TSH of less than 0.10 mIU/L, HR was 1.61 for hip fracture (95% 
CI, 1.21–2.15; 47 events in 510 participants); for any fracture, HR was 1.98 (95% CI, 1.41–2.78; 
44 events in 212 participants); for nonspine fracture, HR was 1.61 (95% CI, 0.96–2.71; 32 events 
in 185 participants); and for spine fracture, HR was 3.57 (95% CI, 1.88–6.78; 8 events in 162 
participants). Risks were similar after adjustment for other fracture risk factors. Endogenous 
subclinical hyperthyroidism (excluding thyroid medication users) was associated with HRs of 1.52 
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(95% CI, 1.19–1.93) for hip fracture, 1.42 (95% CI, 1.16–1.74) for any fracture, and 1.74 (95% 
CI, 1.01–2.99) for spine fracture. No association was found between subclinical hypothyroidism 
and fracture risk.
CONCLUSIONS AND RELEVANCE—Subclinical hyperthyroidism was associated with an 
increased risk of hip and other fractures, particularly among those with TSH levels of less than 
0.10 mIU/L and those with endogenous subclinical hyperthyroidism. Further study is needed to 
determine whether treating subclinical hyperthyroidism can prevent fractures.
Overt hyperthyroidism is an established risk factor for osteoporosis and fractures.1 More 
subtle alterations in thyroid function found in subclinical thyroid dysfunction, defined as 
abnormal thyroid-stimulating hormone (TSH) with normal free thyroxine (FT4), could also 
be associated with increased fracture risk and bone loss.2–4
In prospective cohort studies, data about the association between subclinical thyroid 
dysfunction and fracture risk are in conflict because of inclusion of participants with overt 
thyroid disease3,5 and small sample sizes of participants with thyroid dysfunction6,7 or 
fracture events.8 To our knowledge, no clinical trial has examined the effect of treating 
subclinical thyroid dysfunction on fracture risks. A recent study-level meta-analysis of 
prospective cohorts found an increased fracture risk in subclinical hyperthyroidism, but 
interpretation was limited by population heterogeneity, discrepant definitions of fractures, 
and differing TSH cutoffs for defining subclinical thyroid dysfunction,9 which could not be 
addressed in a study-level meta-analysis.
For these reasons, we performed a pooled analysis of individual participant data of multiple 
large cohorts that assessed the association of subclinical thyroid dysfunction with risk for 
hip fractures, as well as nonspine, clinical spine, and fractures of any location. This 
approach allowed exploration of the relationship of age, sex, and TSH levels with the 
association of subclinical thyroid dysfunction and fractures, and is considered an optimal 
approach for combining evidence.10
Methods
This individual participant data analysis was performed according to a predefined 
protocol.11
Study Selection
We performed a systematic literature search in MEDLINE and EMBASE, from inception to 
March 26, 2015, without language restriction, for prospective cohorts of adults with baseline 
TSH and FT4 levels12 and follow-up for incident fractures. We excluded studies that 
included only participants with overt thyroid dysfunction or individuals taking thyroid-
altering medications (thyroxine, iodine, oral corticosteroids, amiodarone, antithyroid drugs). 
We conducted the search on an Ovid (MEDLINE) server using broadly defined Medical 
Subject Headings: thyroid diseases, hypothyroidism, hyperthyroidism, thyroid hormones, 
thyrotropin, subclinical hyperthyroidism, subclinical hypothyroidism, subclinical 
dysthyroidism or subclinical thyroid, and fractures or osteoporosis. We used a filter to 
extract prospective studies (MEDLINE cohort-study filter)13 but without year limitation. 
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The search was also conducted in EMBASE using similar terms. We searched 
bibliographies of key articles in the field. Two authors (M.R.B. and C.D.W.) independently 
screened the abstracts of the search results and independently assessed the remaining full-
text articles for eligibility. Any disagreement was resolved with the help of a third author 
(D.C.B.).9 We also asked cohorts of the Thyroid Studies Collaboration12,14–16 for 
unpublished prospective fracture data.
All qualifying cohorts were invited to join and provide individual participant data about 
baseline thyroid function, participant characteristics, bone metabolism–altering and thyroid 
medications, and fracture data. We conducted this individual participant data analysis in 
collaboration with investigators from each cohort to resolve data issues.17 Individual cohort 
results were validated against published results. Four cohorts that had not previously 
published fracture data18–21 provided exact procedures for data collection and adjudication 
of fracture data. For comparability with other cohorts in the present analysis, we used the 
random sample of the Osteoporotic Fractures in Men (MrOS) Study7 from 5994 participants 
at the baseline visit.9
Definition of Subclinical Thyroid Dysfunction
We used a uniform TSH threshold to maximize comparability, based on previously 
established thresholds.12 Euthyroidism was defined as having a TSH level of 0.45 to 4.49 
mIU/L. Subclinical hyperthyroidism was defined as having a TSH level of less than 0.45 
mIU/L with normal FT4 levels and was further stratified as suppressed TSH (<0.10 mIU/L) 
and low but not suppressed TSH (0.10–0.44 mIU/L). Subclinical hypothyroidism was 
defined as having a TSH level of 4.50 to 19.99 mIU/L with normal FT4 levels. Participants 
with a missing FT4 level and a TSH level within the range for subclinical thyroid 
dysfunction (1024 participants) were considered as having subclinical thyroid dysfunction 
because most adults with TSH levels in this range have subclinical and not overt thyroid 
dysfunction (eTable 1 in Supplement 1).22 Cohorts using first-generation TSH assays were 
excluded from analyses of subclinical hyperthyroidism because of insufficient sensitivity of 
first-generation thyroid assays.23 Because of greater interstudy method variation, we used 
cohort-specific cutoffs for FT4 and triiodothyronine (T3) levels (eTable 1 in Supplement 1). 
We performed a sensitivity analysis on persistent thyroid dysfunction using repeated TSH 
and FT4 measurements (available in 5 cohorts; follow-up duration in eTable 5 in 
Supplement 1). We performed additional sensitivity analyses excluding participants using 
thyroid-altering medications to estimate the risk associated with endogenous subclinical 
thyroid dysfunction, and excluding participants with missing FT4 levels or abnormal total or 
free T3 levels (measured in 4 out of 13 cohorts).
Outcomes
Our a priori–defined primary outcome was incident hip fracture. Secondary outcomes were 
incident fractures of any location, nonspine, and clinical spine fractures. We standardized 
outcome definitions (eTable 1 in Supplement 1). Incident hip fractures typically included 
fractures of the femoral neck, pertrochanteric, and subtrochanteric fractures, excluding 
pathologic and periprosthetic fractures. Incident nonspine fractures were defined as hip or 
any other nonpathologic fracture excluding the spine, and excluding fractures of the skull or 
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face, ankle, finger, and toe, which are not typically affected by increased bone fragility. 
Incident spine fractures were defined as clinically diagnosed and radiographically confirmed 
thoracic and lumbar spine fractures, excluding cervical and sacral fractures because these 
usually occur due to trauma that is unrelated to bone fragility. We restricted our spine 
fracture outcome to those that were clinically diagnosed and did not consider spine fractures 
identified only by scheduled radiographs, to focus analyses on associations with outcomes 
that are more likely to be symptomatic24 and therefore of greater clinical relevance to 
patients.25 The outcome of any fracture was defined as the first event of either nonspine or 
clinically diagnosed spine fracture. Cohorts with fracture data only for parts of the skeleton, 
such as 1 study with hip fracture data only,8 were not included for this outcome.
In a secondary analysis, we compared fracture risk between thyroxine-treated and untreated 
participants at baseline, irrespective of thyroid function test results, to assess fracture risk 
associated with thyroxine use.
To evaluate study quality, we used the individual criteria of the Newcastle-Ottawa Quality 
Assessment Scale26 (eTable 2 and eMethods in Supplement 1). We performed sensitivity 
analyses excluding cohorts that did not meet different individual criteria of this scale.
Statistical Analyses
We used established methods10,17 with a 2-step approach, first analyzing the association of 
subclinical thyroid dysfunction with outcomes using separate Cox proportional hazard 
models for each cohort (Stata version 12.1), and in a second step calculating pooled 
estimates using random-effects models.27 Time to event was calculated for each outcome 
from baseline to first event. For cohorts with no event in some subgroups of thyroid 
function, penalized maximum likelihood estimation models28 were used to derive hazard 
ratios (HRs) and 95% CIs (SAS version 9.3). Strata with fewer than 6 participants per cohort 
were excluded from pooling due to unreliable estimates. We summarized results using forest 
plots (Review Manager version 5.3.3). We calculated the variance estimate τ2 as a measure 
of heterogeneity in estimates across cohorts. τ2values were prespecified to indicate low 
(≤0.04), moderate (>0.04–<0.36), and high (≥0.36) to indicate heterogeneity.29 P values of 
less than .05 were considered as significant and testing was 2-sided.
Primary analyses were adjusted for age and sex, and then for other known risk factors for 
fractures because some might be potential mediators (eg, body mass index [BMI]) of the 
association between subclinical thyroid dysfunction and fractures. Based on a literature 
search of potential confounders for this association, taking into account their prevalence and 
strength of their association with fractures and possible influence on thyroid function, we 
further adjusted for BMI (calculated as weight in kilograms divided by height in meters 
squared)30 and smoking status,31 which were available in all cohorts. In sensitivity analyses, 
we also accounted for the following characteristics: (1) adjusted for diabetes mellitus32; (2) 
excluded participants who were receiving thyroid-altering medication (oral corticosteroids, 
amiodarone, iodine) or anti-fracture medication (bisphosphonates, calcitonin, selective 
estrogen receptor modulators, parathyroid hormones); (3) limited the analysis to the 8 
studies with formal adjudication or those with the most uniform fracture definition; (4) 
restricted the analysis to participants with repeated measurement of thyroid function to 
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assess the association with persistent thyroid dysfunction; (5) excluded cohorts with loss to 
follow-up rates of greater than 5%; (6) excluded cohorts with fracture ascertainment 
methods other than independent blind assessment or record linkage (eTable 2 in Supplement 
1); (7) excluded participants with missing FT4 levels or abnormal free or total T3; (8) 
excluded studies inconsistent with the proportional hazard assumption; (9) excluded studies 
because of potential publication bias in funnel plots; and (10) applied age-specific TSH 
reference ranges.33
To explore potential sources of heterogeneity, we performed predefined subgroup analyses 
according to age, sex, and TSH levels. We calculated linear P for trend and P for interaction 
for stratified analyses. We used Poisson models to calculate event rates.34 The proportional 
hazard assumption was assessed by graphical methods (log-log graphs) and the Schoenfeld 
test.35 We excluded cohorts violating the proportional hazard assumption in sensitivity 
analyses. We visually assessed funnel plots of age- and sex-adjusted estimates and used the 
Egger test to assess for publication bias.36
Results
Among 1371 studies identified in our literature search, 13 prospective cohorts met inclusion 
criteria (eFigure 1 in Supplement 1). The final sample consisted of 70 298 participants 
(median age was 64 years; 61.3% women), a median (interquartile range) follow-up of 12.1 
(8.3–13.0) years, and a total follow-up of 762 401 person-years (Table). A total of 63 987 
(91.0%) of the participants were euthyroid, 4092 (5.8%) had subclinical hypothyroidism, 
and 2219 (3.2%) had subclinical hyperthyroidism, including 1669 (2.4%) with low but not 
suppressed TSH (0.10–0.44 mIU/L) and 550 (0.8%) with suppressed TSH (<0.10 mIU/L). 
We excluded the Nagasaki Adult Health Study20 from the analysis of subclinical 
hyperthyroidism because it used first-generation thyrotropin assays.
Incident hip fractures were collected in all cohorts except one,18 resulting in a study sample 
of 64 691 participants for the primary outcome. Data were available for any fracture in 28 
561 participants from 8 cohorts, for nonspine fractures in 24 155 participants from 8 studies, 
and for clinical spine fractures in 22 491 participants from 6 cohorts. During follow-up, 
2975 (4.6% in 12 studies) participants had an incident hip fracture, 2528 (9.0% in 8 studies) 
had a fracture in any location, 2018 (8.4% in 8 studies) had a nonspine fracture, and 296 
(1.3% in 6 studies) had a spine fracture.
Although study quality was good (see eMethods and eTable 2 in Supplement 1), 2 cohorts 
did not ascertain fractures with independent blind assessment or record linkage, 5 cohorts 
did not formally adjudicate fractures, and 2 cohorts had a loss to follow-up of greater than 
5%.
Subclinical Hyperthyroidism and Fracture Risk
In age- and sex-adjusted analyses, when compared with euthyroidism, subclinical 
hyperthyroidism was associated with HRs of 1.36 (95% CI, 1.13–1.64; 6.0 vs 4.9 per 1000 
person-years, respectively) for hip fracture, 1.28 (95% CI, 1.06–1.53; 14.4 vs 11.2 per 1000 
person-years) for any fracture, 1.16 (95% CI, 0.95–1.41; 9.9 vs 8.1 per 1000 person-years) 
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for nonspine fracture, and 1.51 (95% CI, 0.93–2.45; 1.8 vs 1.2 per 1000 person-years) for 
spine fracture (Figure 1). Numbers of fracture events and participants, as well as individual 
HRs with CIs for each cohort, are described in Figure 1. Two individual studies found that 
subclinical hyperthyroidism was associated with increased risk for hip fractures 
(Cardiovascular Health Study8 and the Sheffield Study6). No individual study found a 
statistically significant association of subclinical hyperthyroidism with the secondary 
outcomes: any fracture, nonspine fracture, or clinical spine fracture. Although 95% CIs were 
large in some cohorts, heterogeneity was low for all outcomes (all τ2 ≤0.01).
Figure 2 displays stratified analyses for incident hip, any, nonspine, and spine fracture 
events, comparing subclinical hyperthyroidism vs euthyroidism. Men with subclinical 
hyperthyroidism had higher HRs than women for all fracture outcomes, without statistically 
significant interactions except for spine fractures (P for interaction ≤.02). Risks did not 
differ when stratified by age.
Figure 3 displays the association between subclinical hyperthyroidism and the risk of 
fracture by TSH category. Risks for hip, any, and spine fracture were higher in participants 
with lower TSH levels. TSH levels of less than 0.10mIU/L were not associated with 
increased risk of non-spine fracture. The multivariable analysis yielded similar results 
(eTable 3 in Supplement 1).
Sensitivity analyses excluding participants with missing FT4, T3, or those who had been 
prescribed antiosteoporotic medication; restricting the analysis to studies with formal 
adjudication or those with the most uniform fracture definition; or excluding studies 
inconsistent with the proportional hazard assumption (possible publication bias in funnel 
plots), with a greater than 5% loss to follow-up, with fracture ascertainment methods other 
than independent blind assessment, or record linkage all yielded similar results (eTables 4–6 
in Supplement 1). After excluding participants who had been prescribed thyroid or 
antithyroid medication at baseline (4%), participants with endogenous subclinical 
hyperthyroidism had statistically significant increased risk estimates for all fracture 
outcomes except for nonspine fractures. Although point estimates were similar for persistent 
thyroid dysfunction, our findings were not statistically significant with larger CIs. 
Restricting the analysis to 9 cohorts with previously published fracture data generally 
yielded similar risk estimates (eTable 6 in Supplement 1) without statistically significant 
interactions, when compared to 4 cohorts with unpublished fracture data. When restricting 
analyses to 4 cohorts with unpublished fracture data, results were not statistically significant.
Subclinical Hypothyroidism and Fracture Risk
We found no association between subclinical hypothyroid-ism and fracture risks either 
overall (eFigure 2 in Supplement 1) or in stratified analyses (eTable 7 in Supplement 1), 
with an HR compared with euthyroid participants of 0.96 (95% CI, 0.83–1.10) for hip 
fracture, 1.02 (95% CI, 0.89–1.18) for any fracture, 1.06 (95% CI, 0.90–1.24) for nonspine 
fracture, and 0.96 (95% CI, 0.59–1.55) for spine fracture. Sensitivity analyses did not 
change results (eTable 8 in Supplement 1).
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Treatment With Thyroxine and Fracture Risk
When comparing between participants treated with thyroxine at baseline vs untreated 
participants regardless of thyroid function, treatment with thyroxine was not associated with 
any of the fracture outcomes (eTable 9 in Supplement 1).
Discussion
In this analysis of 70 298 individual participants from 13 prospective cohorts, subclinical 
hyperthyroidism was associated with an increased risk for hip and other fractures, with the 
highest risks in individuals with suppressed TSH (<0.10 mIU/L) and in those with 
endogenous subclinical hyperthyroidism. Conversely, our study found no association 
between subclinical hypothyroidism and fractures. Our pooled data analysis demonstrates 
that subclinical hyperthyroidism was associated with increased fracture risk and provides 
insight on defined subgroups.
To our knowledge, no pooled individual participant data analysis has previously assessed the 
association of subclinical thyroid dysfunction and fracture events. The Cardiovascular 
Health Study prospectively followed a cohort of 3567 older adults and found that in men, 
there was an association between increased hip fracture risk and subclinical hyperthyroidism 
(HR, 3.07; 95% CI, 1.11–8.46), as well as subclinical hypothyroidism (HR, 1.86; 95% CI, 
1.09–3.16).8 Our results confirm the association of subclinical hyperthyroidism with risk of 
hip fracture. A prospective case-cohort study of 686 women aged 65 years and older found 
an odds ratio of 4.5 (95% CI 1.3–15.6) for spine fracture, detected in serial radiographs in 
women with a TSH level 0.10 mIU/L or less, compared with normal TSH levels after a 
mean follow-up of 3.7 years.3 Our study also found that endogenous subclinical 
hyperthyroidism was associated with increased risk of clinically diagnosed spine fractures 
(HR, 1.74; 95% CI, 1.01–2.99). However, because not all radiographic fractures are 
clinically diagnosed,43 it is difficult to directly compare results with the prior study. 
Although there is some evidence that thyroid hormone level is associated more strongly with 
changes in cortical than in trabecular bone,44,45 we did not observe a stronger association 
with a more cortical (hip) vs a more trabecular (spine) fracture site.
Thyroid function may influence fracture risk through several mechanisms. First, thyroid 
hormones have been shown to have effects on osteoclasts and osteoblasts, with thyroid 
status in the upper normal range or excess thyroid hormones leading to accelerated bone 
turnover with bone loss and increased fracture risk.4 Second, the association of subclinical 
hyperthyroidism with increased fracture risk might be mediated by an increased risk of 
falls46 through effects on muscle strength and coordination.41,47 Third, the increase in 
fracture risk could be related to thyroxine supplementation. In the TEARS study, 
participants receiving thyroid hormone replacement therapy had a higher rate of fractures 
when TSH was suppressed, compared with treated euthyroid participants (adjusted HR, 
2.02; 95% CI, 1.55–2.62). However, participants with overt thyroid dysfunction might have 
been included in the TEARS study. FT4 levels were not measured and the study did not 
include an untreated control group.5 Another nested case-control study of more than 120 000 
prevalent levothyroxine users showed that levothyroxine use was associated with increased 
fracture risk when compared with discontinuation of levothyroxine more than 6 months 
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previously. However, TSH levels were not considered in these analyses.48 Our results 
showed an association of subclinical hyperthyroidism with increased risk of all fracture 
outcomes except nonspine fractures when thyroid medication users (thyroxine and 
antithyroid medication) were excluded from analyses. These results suggest that endogenous 
hyperthyroidism is associated with increased fracture risk. Endogenous subclinical 
hyperthyroidism may be undetected for years because symptoms of subclinical 
hyperthyroidism are often nonspecific or absent. This phenomenon has the potential to lead 
to a greater length of time for adverse associations with bone metabolism. Baseline 
thyroxine use was not associated with increased fracture risk when TSH levels were not 
taken into account. A possible explanation for this is that patients receiving replacement 
therapy have more frequent thyroid function tests followed by thyroxine dosage change 
when overtreatment is detected, and thus do not exhibit a long-standing form of subclinical 
hyperthyroidism.
Our study has important strengths. First, to our knowledge, this is the largest study of adults 
with subclinical thyroid dysfunction and prospective follow-up of fracture outcomes. An 
individual participant data analysis is not subject to potential aggregation bias arising in 
study-level meta-analyses49 and is therefore seen as the optimal approach to combining 
evidence across multiple studies and performing time-to-event analyses.50 In addition, 
individual participant data analysis enables use of standardized definitions of predictors and 
outcomes, and standardized adjustment for confounding factors,10 thus producing more 
robust results. We were also able to include 4 cohort studies that have not previously 
published their data on thyroid dysfunction and fractures (Busselton Health Study,19 
PROSPER Study,18 InCHIANTI Study,21 and Nagasaki Adult Health Study20), and all 
prospective cohorts identified through our systematic search agreed to participate, which 
increased our power to detect potential associations.
Our study has limitations. First, in the majority of cohorts, thyroid function was assessed at 
baseline only, which is a limitation of most published large cohorts on the risk of subclinical 
thyroid dysfunction.12,38 Subclinical hypothyroidism has an annual rate of 2% to 6% for 
spontaneous progression to overt thyroid dysfunction,51 while 15% to 65% revert to normal 
thyroid function over follow-up periods of 1 to 6 years.52 Subclinical hyperthyroidism 
similarly progresses to overt disease in 1% to 2% of affected individuals per year.53,54 In our 
pooled data, 5.3% of participants with baseline subclinical hyperthyroidism developed overt 
hyperthyroidism on follow-up thyroid function assessment vs 1.6% of participants when 
excluding thyroxine use at baseline (endogenous form). A sensitivity analysis, restricted to 
participants with persistent subclinical thyroid dysfunction using repeated thyroid function 
measurement in 5 cohorts with available data, yielded similar HRs for hip and any fracture 
outcomes, with nonstatistically significant results, possibly due to smaller sample sizes. 
Second, it was not possible to achieve a uniform definition for each fracture type across all 
cohorts. Sensitivity analyses limited to cohorts with the most uniform fracture definition, 
however, yielded similar results. Third, we defined subclinical hyperthyroidism by low TSH 
and normal FT4 levels because T3 levels were measured only in 4 cohorts. Consequently, 
participants with T3 toxicosis may have been defined as having subclinical hyperthyroidism, 
but results remained similar in sensitivity analyses excluding participants with abnormal T3 
levels in the cohorts that had this measurement available. Likewise, we may have included 
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participants with nonthyroidal illness from other cohorts in which T3 levels were not 
measured. Fourth, only 8 of 13 studies formally adjudicated fracture outcomes; sensitivity 
analyses limited to these studies yielded similar results. Fifth, our pooled data contained 
relatively few young adults and a primarily white population, thus limiting generalizability. 
Sixth, in spite of the large number of participants, event numbers were low for some 
outcomes, such as clinical spine fractures, limiting power for subgroup analyses. Seventh, 
younger participants may have been more likely to experience traumatic fractures and 
mechanism of injury was not collected in most cohorts. However, fractures in locations not 
typically associated with osteoporosis or low bone mass density were excluded. Eighth, 
history of fracture or history of maternal and parental hip fracture were unavailable for most 
participants or we could not rule out the possibility of residual confounding.
Current guidelines recommend that treatment of subclinical hyperthyroidism should be 
strongly considered if TSH is persistently lower than 0.1 mIU/L in all individuals aged 65 
years or older and that treatment should also be considered if TSH is low but at least 0.1 
mIU/L in individuals who are at least 65 years old.55 Our results from pooling data of all 
available prospective cohorts, showing increased fracture risk in subclinical hyperthyroidism 
with even higher risk for participants with TSH levels of less than 0.10 mIU/L, are 
consistent with these recommendations. Due to the previously mentioned limitations, 
evidence from observational data should be used with caution in clinical decision making. 
Some small randomized controlled trials (14–66 participants) have studied the short-term 
effect (follow-up time of 6–14 months) of subclinical thyroid dysfunction treatment on bone 
mineral density with conflicting results,56–59 but no randomized controlled trial has been 
conducted regarding treatment of subclinical thyroid dysfunction to reduce fracture risk. 
There are also no studies comparing the relative benefit of treatment of subclinical 
hyperthyroidism vs treatment with bisphosphonates or other antifracture agents.
Conclusions
Subclinical hyperthyroidism was associated with an increased risk of hip and other fractures, 
particularly among those with TSH levels lower than 0.10 mIU/L and those with 
endogenous subclinical hyperthyroidism. Further study is needed to determine whether 
treating subclinic al hyperthyroidism can prevent fractures.
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Figure 1. Association Between Subclinical Hyperthyroidism and Fracture Risk
Hazard ratios (HRs) were adjusted for age and sex. Data marker sizes are proportional to the 
inverse of the variance of the HRs. Error bars indicate 95% CIs. Not every outcome was 
available for each study. Calculations of τ2 were used to measure heterogeneity in effect 
estimates across cohorts, with a prespecified τ2 (≤0.04) indicating low heterogeneity and 
greater than 0.04 to 0.36 indicating moderate heterogeneity.
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Figure 2. Stratified Analyses for the Association Between Subclinical Hyperthyroidism and 
Fracture Risk
All hazard ratios (HRs) were age and sex adjusted. Error bars indicate 95% CIs. The 
multivariable analysis yielded similar results (eTable 3 in Supplement 1).
aThe PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) Study was not 
included because follow-up data were only available for any fracture.
bThese HRs were adjusted for sex and age as a continuous variable to avoid residual 
confounding within age strata.
cThe HUNT (Nord-Trøndelag Health Study), Cardiovascular Health Study, Sheffield, and 
OPUS (Osteoporosis and Ultrasound Study) studies were not included because follow-up 
data for any fracture were not available.
dThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, and PROSPER studies were not 
included because follow-up data for nonspine fractures were not available.
eThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, Sheffield, OPUS, and 
PROSPER studies were not included because follow-up data for spine fractures were not 
available.
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Figure 3. Association Between Subclinical Hyperthyroidism and Fracture Risk Categorized by 
Thyroid-Stimulating Hormone Level
All hazard ratios (HRs) were age and sex adjusted. Error bars indicate 95% CIs. The 
multivariable analysis yielded similar results (eTable 3 in Supplement 1).
aThe PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) Study was not 
included because follow-up data were only available for any fracture.
bThe HUNT (Nord-Trøndelag Health Study), Cardiovascular Health Study, Sheffield, and 
OPUS (Osteoporosis and Ultrasound Study) studies were not included because follow-up 
data for any fracture were not available.
cThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, and PROSPER studies were not 
included because follow-up data for nonspine fractures were not available.
dThe HUNT, Cardiovascular Health Study, Leiden 85-Plus, Sheffield, OPUS, and 
PROSPER studies were not included because follow-up data for spine fractures were not 
available.
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